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CC BY-NC-ND license (http://creativAbstract Rectal cancer is a formidable disease with high recurrence and metastasis rates,
particularly before total mesorectal excision (TME) was first described by Heald and Ryall in
1982. Through this ground-breaking operative procedure, rectal cancer has become a poten-
tially curable condition. Traditional abdominoperineal resection has gradually been replaced
with TME and coloanal anastomosis for resectable low rectal cancer. In addition, improved
overall survival and decreased local recurrence rates have been achieved. For locally advanced
(cT3/4, cN1/2) low rectal cancer (lower tumor margin< 6 cm above the anal verge), sphincter
preservation is a major concern in cancer treatment. Randomized controlled trials have shown
that neoadjuvant chemoradiation therapy (CRT) leads to a decrease in tumor size and en-
hances the likelihood of tumor resectability and sphincter preservation with low local recur-
rence rates. Therefore, neoadjuvant CRT followed by TME is the standard treatment
guideline used worldwide for patients with low rectal cancer. However, one must understand
the basic principles of TME to know why this procedure should be employed to treat locally
advanced low rectal cancer. We therefore performed a minireview to explore how surgeons
address this problem, how to help patients live longer, and how to reduce the occurrence of
perioperative morbidities.
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Since total mesorectal excision (TME) was first described by
Heald and Ryall1 in 1982, rectal cancer has become a
potentially curable condition. Traditional abdominoper-
ineal resection has gradually been replaced with TME and
coloanal anastomosis for resectable low rectal cancer. In
addition, improved overall survival and decreased local
recurrence rates have been achieved. Furthermore, for
locally advanced (cT3/4, cN1/2) low rectal cancer (lower
tumor margin< 6 cm above the anal verge), sphincter
preservation is a major concern in cancer treatment. Ran-
domized controlled trials have shown that neoadjuvant
chemoradiation therapy (CRT) leads to a decrease in tumor
size and increases the likelihood of tumor resectability and
sphincter preservation2,3 with low local recurrence rates.
Therefore, neoadjuvant CRT followed by TME is the stan-
dard treatment guideline used worldwide for patients with
low rectal cancer.
2. Clinical staging evaluation
Computed tomography, which determines the clinical
staging of low rectal cancer, is widely used worldwide
because of easy accrual, short execution time, and rela-
tively low costs. Rectal tumor shrinkage after neoadjuvant
CRT correlates positively with clinical and pathologic
changes.4e6 However, until now, magnetic resonance im-
aging (MRI) for selecting node-positive patients, and
transrectal ultrasound (TRUS) for determining tumor inva-
sion depth have been the gold standards for clinical staging.
Similar to other types of ultrasound, TRUS is operator
dependent. However, with an experienced operator, TRUS
can be as effective as MRI in detecting perirectal lymph-
adenopathy.7 Nevertheless, using MRI to determine
whether the circumferential resection margin (CRM) is
compromised during TME is another major benefit of using
this approach to determine whether patients require neo-
adjuvant radiotherapy (RT).8e10 Finally, before we depend
totally on modern technology, a digital examination should
always be performed, which can be as accurate as TRUS or
MRI in tumor staging when performed by an experienced
surgeon.
3. Evolutionary process of chemotherapy,
radiotherapy, and chemoradiation therapy
Prior to the widespread acceptance of TME, randomized
controlled trials had confirmed that using adjuvant
chemotherapy (CT) and RT could significantly reduce local
recurrence rates and improve overall survival rates for
rectal cancer patients.11e13 In addition, general consensus
indicates that neoadjuvant RT has the effects of steriliza-
tion of the mesorectal lymphatic channels, tumor bulk
reduction in improving resectability and increasing
sphincter preservation, exclusion of the small bowel from
the radiation field, improved response in untreated tumors,
and superior function of nonirradiated neorectum.14 TME
and RT have merged gradually, such that both CT and RT,
which are used prior to surgery, enable superior localcontrol and higher overall survival, setting the foundation
for subsequent randomized controlled trials in validating
their effects.15e18 After TME became the dominant surgical
procedure for low rectal cancer, more randomized
controlled trials were executed, revealing a phenomenon
that neoadjuvant RT could reduce local recurrence rates,
even after TME surgery.19e21 The superior local control
ability of neoadjuvant RT was confirmed by both the Dutch
TME trial after 12 years of follow-up22 and the German
Rectal Cancer Study Group trial after 11 years of follow-
up.24. Short- versus long-course radiotherapy
The choice of long- or short-course RT has long been an
active debate; each choice has its own proponents. How-
ever, in improving the tumor downsizing effect, long-course
RT is superior to short-course RT, although short-course RT
with a longer waiting period can still achieve the same ef-
fect, as reported by the Stockholm III trial.23 Regarding
local control, the effectiveness of short-course RT is at
least comparable with that of long-course RT.
Table 1 summarizes crucial randomized controlled trials
about neoadjuvant and adjuvant RT, CT, and CRTwith long-
term follow-up results.5. Neoadjuvant chemotherapy regimens
(infusional 5-fluorouracil, oral 5-fluorouracil,
and other agents)
Adding 5-fluorouracil (5-FU) CT to RT in gastrointestinal
cancer treatment to improve overall survival (compared
with RT alone) was approved in 1969.24 To determine the
effect of neoadjuvant CT, the European Organization for
Research and Treatment of Cancer 22921 randomized
controlled trial reported that combining CT with RT pre-
operatively could improve pathologic response rates and
the downsizing effects.25 Therefore, to decrease the
tumor bulk to improve the likelihood of sphincter pres-
ervation, using long-course instead of short-course CRT is
a more rational choice, which is similar to a finding re-
ported in the German Rectal Cancer Study trial. Regarding
the choice of CT, infusional 5-FU/leucovorin with RT is
currently the gold standard. Oral 5-FU (uracil, tegafur,
and capecitabine) with RT has been proven to have ther-
apeutic effects similar to those of infusional 5-FU.26e28
The addition of other chemotherapeutic or target ther-
apy agents, including oxaliplatin, irinotecan, bev-
acizumab, and cetuximab, is currently being investigated
in randomized controlled trials, but it is not considered in
standard treatment plans because of higher toxicities,
despite similar pathologic complete response (PCR)
rates.29 Notably, in 2015, the German Rectal Cancer Study
Group published remarkable results for a randomized
controlled trial, stating that if oxaliplatin were incorpo-
rated into both neoadjuvant 5-FU-based CRT and adjuvant
CT for patients with locally advanced rectal cancer, bet-
ter disease-free survival could be achieved with accept-
able treatment-related toxicity and death.30 Because this
large randomized controlled trial was performed by an
Table 1 Crucial randomized controlled trials about neoadjuvant and adjuvant RT and CT.
Trial Years Protocol Long-term results Follow-up (y)
Swedish Rectal
Cancer Trial
1987e1990 25-Gy neoadjuvant RT vs.
surgery
Neoadjuvant RT decreased
local recurrence rates & is
beneficial for overall &
cancer-specific survival
13
Dutch TME Trial 1996e1999 25-Gy neoadjuvant RT vs.
surgery
Neoadjuvant RT reduced local
recurrence by 50% with
improved cancer-specific





1995e2002 5040-cGy neoadjuvant CRT plus
adjuvant C/T vs. 5580 cGY
adjuvant CRT












EORTC 22921 1993e2003 45-Gy neoadjuvant RT vs.
45-Gy neoadjuvant CRT vs.
45-Gy neoadjuvant RT plus
adjuvant C/T vs. 45-Gy
neoadjuvant CRT plus adjuvant
C/T
Adjuvant fluorouracil-based
chemotherapy does not affect
disease-free or overall survival
after neoadjuvant RT or CRT
11
Stockholm III 1998e2010 25-Gy neoadjuvant RT vs.
25-Gy neoadjuvant RT plus
delayed surgery
Increased tumor downstaging if
surgery after 4e8 wks
Not
applicable
CRTZ chemoradiation therapy; CTZ chemotherapy; EORTCZ European Organisation for Research and Treatment of Cancer;
RTZ radiotherapy; TMEZ total mesorectal excision.
Locally advanced low rectal cancer 85acclaimed study group, we believe that more oxaliplatin-
related neoadjuvant trials will be reported by surgical and
oncological societies in the future. Accordingly, based on
our personal series, the use of infusional 5-FU and a
concomitant RT protocol can be expected to lower
treatment toxicity without compromising the desirable
treatment effects of neoadjuvant CRT in standard low
rectal cancer patients.31 Finally, the choice of whether
postoperative adjuvant CT should be given is controver-
sial, particularly for ypT0-2N0 patients. A meta-analysis of
the Cochrane review demonstrated that adjuvant CT after
rectal cancer resection improved local control of the
disease32 but not specifically under the premise of neo-
adjuvant CRT. To date, randomized trials targeting this
issue do not support the use of postoperative CT after
neoadjuvant CRT for operable rectal cancer. Additional
appropriately designed studies are necessary to address
this concern in the future.33e35
6. Total mesorectal excision, minimally
invasive surgery, and pelvic lymph node
dissection
TME is the cornerstone of curative treatment for low rectal
cancer patients. The natural barriers of the bony structure
and pelvic organs render low pelvic dissection difficult,
even in open surgery. With rapid advancements in tech-
nology, higher magnification and a clearer optic view canbe obtained in minimally invasive surgery (MIS). In addition,
faster tissue-dividing and safer vessel-sealing ability could
be achieved with new ultrasonic or bipolar energy equip-
ment. Thus, currently, TME with MIS in a narrow male pelvis
can be performed safely with low risk of morbidity.
Although relatively new, the prevalence of MIS in rectal
cancer surgery has increased rapidly worldwide. Random-
ized controlled trials and many retrospective studies have
confirmed that MIS, either laparoscopic or robotic, can
achieve comparable surgical quality with similar morbidity
and mortality to open surgery.36e38 Another aspect of sur-
gery is about pelvic lateral lymph node dissection, which is
an essential part of surgery for low rectal cancer in Japan,
although it is not frequently performed in Taiwan. Ac-
cording to reports from both Western societies and Japan,
lateral lymph node dissection is equivalent to CRT in terms
of local control of the disease. A noninferiority trial
(JCOG0212) was conducted in Japan to examine the
effectiveness of TME and lateral lymph node dissection
compared with TME alone.39 The results of that study are
expected to clarify the therapeutic benefits and long-term
outcomes of this surgical procedure. By contrast, rectal
cancer surgery has included the so-called “down-to-up”
approach since the first report of transanal TME (or reverse
TME) in 2010, which claimed it to be an easier surgical
approach with shorter operation time for low rectal can-
cer.40 Increasingly more medical facilities have published
reports of the short-term outcomes of this reversed pro-
cedure regarding specimen quality and operative
86 P.-C. Chen, J.-C. Leemorbidities; basically, perioperative outcomes are compa-
rable with those of traditional laparoscopic surgery.41,42
More studies are currently underway to confirm the safety
and feasibility of this procedure.
7. Timing of surgery after neoadjuvant
chemoradiation therapy
The optimal timing of interval surgery remains unclear.
When a surgeon chooses either short- or long-course RT,
surgery should be undertaken within 2 weeks or after 6
weeks, respectively, to avoid severe tissue edema and
postoperative morbidity. However, to gain the benefit of
tumor downsizing and sphincter preservation, long-course
RT is the more rational choice. According to a German rectal
cancer study, a duration of 6e8 weeks post-RT can avoid
severe surgical morbidities and significantly raise the like-
lihood of sphincter preservation.20 Currently, longer waiting
times are supported by evidence from retrospective studies,
showing that a higher PCR rate can be expected for longer
waiting times without causing greater surgical morbidity. On
the basis of a retrospective analysis of a Dutch surgical
colorectal audit database, the highest PCR rates occurred
when operations were postponed for 10e11 weeks.43 How-
ever, the only randomized controlled trial addressing this
issue to date is the Lyon R90-01 trial in 1999,44 in which
patients were randomized into short (<2 weeks) and long
(6e8 weeks) course groups, and 6e8-week intervals became
the current standard practice. Hence, additional prospec-
tive studies are necessary to address this issue.
8. Prognostic factors of surgical specimen
(distal resection margin, circumferential
resection margin, and tumor regression grade)
Regarding the surgical quality affecting both local and
distant metastasis, three factors have been identified to be
of crucial prognostic value: the distal resection margin
(DRM), circumferential resection margin (CRM), and lymph
node yield. The DRM and CRM are associated with local
control of a disease, disease-free survival, and overall
survival.45e47 Traditionally, 2 cm of the distal margin is
considered adequate. However, increasingly more retro-
spective series have demonstrated that 1 cm appears to be a
sufficient DRM in low rectal cancer patients who received
neoadjuvant CRT.48 In addition, tumor involvement over the
CRM has a negative effect on the 5-year local recurrence,
distant metastasis, and overall survival rates in patients
with low rectal cancer. Frequently, fewer than 12 lymph
nodes can be harvested despite maintaining vigorous surgi-
cal standards in low rectal cancer patients if neoadjuvant
CRTwas performed.49,50 However, the persistence of lymph
nodemetastasis after a patient undergoes neoadjuvant RT is
associated with a poor prognosis and survival, and may serve
as a marker of aggressive tumor behavior.51,52 Another
crucial concern about the treatment response is the path-
ologic tumor regression grade, which is graded 1e5, ac-
cording to the Mandard score. A PCR, which is Grade 1, is a
major prognostic factor in rectal cancer patients who
receive neoadjuvant CRT.53e55 A rectal cancer specimenwith a PCR is an excellent marker for both exceptional local
control and disease-free survival. The PCR can be affected
by various factors including CT regimen, RT dosage, and
surgical interval. Large-scale retrospective studies have
demonstrated that PCR rates could be increased if the sur-
gical interval was prolonged up to 12 weeks. However,
whether higher PCR rates from longer waiting times trans-
late into improved local and systemic control is unknown.9. Stool diversion after total mesorectal
excision and postoperative anal function
Routine temporary defunctioning stoma construction after
TME was previously considered controversial.56 However,
current opinions have gradually shifted to support the
routine construction of defunctioning stoma to minimize
postoperative complications.57e59 A meta-analysis demon-
strated that anastomotic leakage can have a negative effect
on local recurrence and cancer-specific survival in patients
with colorectal cancer.60 In our personal series, a defunc-
tioning loop stoma was created for every low rectal cancer
patient treated with neoadjuvant CRT and a sphincter-saving
procedure, achieving extremely low rates of early and late
surgical complications. Based on our experience and that of
other researchers, we believe that routine defunctioning
stoma construction prevents significant postoperative com-
plications, including fistula formation from anastomotic
leakage and subsequent permanent colostomy, and guaran-
tees a smooth and safe treatment course.31
For patients undergoing TME and coloanal anastomosis,
postoperative anal function recovery is crucial. In addition,
neoadjuvant RT was reported to delay postoperative ano-
rectal function recovery.61 In our personal series, with the
use of the Memorial Sloan-Kettering Cancer Center anal
function score, approximately 50% of the patients reported
poorefair anal function 1 month after surgery, but this
could be improved to fairegood 2 years after a straight
coloanal anastomosis procedure.31 The benefit of a straight
coloanal anastomosis is that the splenic flexure does not
need to be taken down routinely during surgery, reducing
the likelihood of operative morbidity. A previous report and
our experience have shown that 2 years after a straight
coloanal anastomosis, anal function would be comparable
with that of patients who underwent J-pouch coloanal
anastomosis or T-coloplasty.6210. Now and the future
To date, treatment of locally advanced low rectal cancer
patients through neoadjuvant CRT with infusional 5-FU can
minimize associated morbidities and achieve a comparable
pathologic response. TME at 6e11 weeks after RT with
routine defunctioning stoma construction can achieve
excellent local control and guarantee a smooth and safe
treatment course. After 30 years of evolvement, these
procedures are the gold-standard treatment options.
However, additional paradigm-shifting ideas are continually
proposed. More individually tailored approaches, including
the choice of radiation for individual patients, a nonoper-
ative organ-preserving approach for selected patients, or
Locally advanced low rectal cancer 87precise treatment regimens based on the treatment
response for every patient and tumor, are gaining increas-
ingly more attention from surgical societies worldwide.63
Thus, the future of treating low rectal cancer is expected
to remain exciting and challenging.References
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